

MEDICAL DIRECTIVE

Family Health Team

Taddle Creek

Fitle:	Fecal Occult Blood Test	Number:	TCFHT-MD01
Activation Date:	01-January-2014	Review Date:	21-March-2019
Next Review Date:	21-March-2020		
`noncoring/Contact	Dr. Mira Barman		
Sponsoring/Contact Person(s)			
name, position,	790 Bay St. Suite 302 Toronto, ON M5G 1N8		
contact particulars):	416-585-9555		
	Vicki McGregor, RN		
	790 Bay St. Suite 302		
	Toronto, ON M5G 1N8		
	416-585-9555		
	Sherry Kennedy, Executive 790 Bay Street, Suite 306	Director – <u>skennedy@t</u>	<u>tctht.on.ca</u>
	Toronto, Ontario M5G 1N8 416-260-1315, x307		
Order and/or Delegat	416-260-1315, x307	Appendix Attached: 🛛 🗖	Yes 🗹 No
	416-260-1315, x307 ed Procedure: er a Fecal Occult Blood Test (I	OBT) for colorectal ca	
mplementers may ord	416-260-1315, x307 ed Procedure: er a Fecal Occult Blood Test (I onditions identified in this dire	OBT) for colorectal can ctive.	ncer (CRC) screening in
mplementers may ord	416-260-1315, x307 ed Procedure: er a Fecal Occult Blood Test (I onditions identified in this dire	OBT) for colorectal can ctive. Appendix Attached: 2	ncer (CRC) screening in
mplementers may ord accordance with the co Recipient Patients:	416-260-1315, x307 ed Procedure: er a Fecal Occult Blood Test (I onditions identified in this dire	OBT) for colorectal can ctive.	ncer (CRC) screening in
mplementers may ord ccordance with the co Recipient Patients: Recipients must: Be active patients of	416-260-1315, x307 ed Procedure: er a Fecal Occult Blood Test (I onditions identified in this dire	FOBT) for colorectal can ctive. Appendix Attached: 🗹 Title: Appendix A – Authoria	ncer (CRC) screening in Yes DNo zer Approval Form
mplementers may ord ccordance with the co Recipient Patients: Recipients must:	416-260-1315, x307 ed Procedure: er a Fecal Occult Blood Test (I onditions identified in this dire	FOBT) for colorectal can ctive. Appendix Attached: 🗹 Title: Appendix A – Authoria	ncer (CRC) screening in Yes DNo zer Approval Form
Recipients must: Be active patients of Authorizer Approva	416-260-1315, x307 ed Procedure: er a Fecal Occult Blood Test (I ponditions identified in this dire of a TCFHT primary care provid al Form	FOBT) for colorectal can ctive. Appendix Attached: 🗹 Title: Appendix A – Authoria	ncer (CRC) screening in Yes DNo zer Approval Form
mplementers may ord accordance with the co Recipient Patients: Recipients must: Be active patients of Authorizer Approva Be 50 to 74 years o	416-260-1315, x307 ed Procedure: er a Fecal Occult Blood Test (I ponditions identified in this dire of a TCFHT primary care provid al Form	OBT) for colorectal car Cobrementation Appendix Attached: Itile: Appendix A – Authorization der who has approved	ncer (CRC) screening in Yes DNo zer Approval Form this directive by signing th
mplementers may ord ccordance with the co Recipient Patients: Be active patients of Authorizer Approva Be 50 to 74 years of Meet the condition	416-260-1315, x307 ed Procedure: er a Fecal Occult Blood Test (I onditions identified in this dire of a TCFHT primary care provid al Form if age* is of average risk for colorecta	OBT) for colorectal cal COBT) for colorectal cal ctive. Appendix Attached: Appendix Attached: Itile: Appendix A – Authoriz Address approved Address approved I cancer, as identified i 	ncer (CRC) screening in Yes DNo zer Approval Form this directive by signing th in this directive
mplementers may ord accordance with the co Recipient Patients: Recipients must: Be active patients of Authorizer Approva Be 50 to 74 years of Meet the condition	416-260-1315, x307 ed Procedure: er a Fecal Occult Blood Test (I onditions identified in this dire of a TCFHT primary care provid al Form f age*	OBT) for colorectal cal COBT) for colorectal cal ctive. Appendix Attached: Appendix Attached: Itile: Appendix A – Authoriz Address approved Address approved I cancer, as identified i 	ncer (CRC) screening in Yes DNo zer Approval Form this directive by signing th in this directive
 mplementers may ord accordance with the constraints Recipient Patients: Be active patients of Authorizer Approva Be 50 to 74 years of Meet the condition 	416-260-1315, x307 ed Procedure: er a Fecal Occult Blood Test (I ponditions identified in this dire of a TCFHT primary care provid al Form if age* is of average risk for colorecta years old and their 50 th birtho	FOBT) for colorectal call FOBT) for colorectal call ctive. Appendix Attached: Image: Colorectal call Appendix Attached: Image: Colorectal call Ittle: Appendix A — Authoriz Image: Colorectal call der who has approved Image: Colorectal call l cancer, as identified i Image: Colorectal call day is within 60 days of Image: Colorectal call	ncer (CRC) screening in Yes DNo zer Approval Form this directive by signing th in this directive

Implementer must be a TCFHT employed Regulated Health Care Provider or Physician Assistant (under the supervision of a physician).

Implementers must have completed the following training and sign the Implementer Approval Form:

- Review the entire Health Care Professionals section of the Ontario Ministry of Health and Long Term Care ColonCancerCheck program website, accessible from: <u>http://www.health.gov.on.ca/en/pro/programs/coloncancercheck/role.aspx</u>
- Review the following Cancer Care Ontario articles:
 - a. Cancer Care Ontario. (2016). *Screening Guidelines Colon Cancer*, accessible from: <u>https://www.cancercare.on.ca/pcs/screening/coloscreening/cccstandardsguidelines/</u>
 - b. Cancer Care Ontario. (2016). *About ColonCancerCheck,* accessible from: <u>https://www.cancercareontario.ca/en/cancer-care-ontario/programs/screening-programs/colon-cancer-check-colorectal-screening</u>
 - c. Cancer Care Ontario (2018). *Colorectal Cancer Screening Pathway Map*. Accessible from: <u>https://www.cancercareontario.ca/en/pathway-maps/colorectal-cancer</u>
- Review the following articles, accessible from http://www.UptoDate.com:
 - a. Doubeni, C. (2018). Screening for colorectal cancer: Strategies in patients at average risk.
 - b. Ramsey, SD & Grady, WM. (2019). *Screening for colorectal cancer in patients with a family history of colorectal cancer or advanced polyp.*
 - c. Doubeni, C. (2019). *Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy.*

Indications:

Appendix Attached:☑ Yes□ NoTitle: Appendix C - CRC (FOBT) Screening Requisition

Implementers may order a ColonCancerCheck FOBT for eligible patients who are 50 to 74 years old* who are at average risk of CRC. Implementers may order the FOBT using a Ministry of Health and Long-Term Care Laboratory Requisition.

Eligible for FOBT (Average Risk):

- Patients ages 50-74 years old* with no first-degree relatives (parent, sibling or child) who have been diagnosed with CRC (Cancer Care Ontario, 2018).
- No personal history of pre-cancerous colorectal polyps requiring surveillance (Cancer Care Ontario, 2018).
- No personal history of inflammatory bowel disease (i.e., ulcerative colitis or Crohn's disease) (Cancer Care Ontario, 2018).
- No FOBT within the last 2 years (Cancer Care Ontario, 2018)
- No colonoscopy or flexible sigmoidoscopy within the last 10 years (Cancer Care Ontario, 2018)

Not eligible for FOBT (Increased Risk):

- Age 50 to 74 years old OR 10 years younger than the earliest age of diagnosis of the family member with CRC (whichever comes first) (Cancer Care Ontario, 2018)
- Patients who have a personal history of CRC (Cancer Care Ontario, 2018)

TCFHT-MD01_Fecal Occult Blood Test

- Patients with a personal history of pre-cancerous colorectal polyps requiring surveillance (Cancer Care Ontario, 2018)
- Patients who have a family history that includes one or more first-degree relatives who have been diagnosed with CRC (Cancer Care Ontario, 2018).
- Patients who have a personal history of inflammatory bowel disease (i.e., ulcerative colitis or Crohn's disease) (Cancer Care Ontario, 2018).

* Eligible if they are 49 years old and their 50th birthday is within 60 days of application of the directive

Consent:	Appendix Attached: 🗹 Yes 🗆 No
	Title: Appendix D – Turning 50 CRC Screening (FOBT)
	Letter

The patient has enrolled with their provider at the Taddle Creek FHT. Therefore, consent to receive health information and notification of screening eligibility is implied. A letter will accompany the FOBT kit in the mail, which will encourage the patient to contact their provider should they have questions. Once receiving the FOBT kit in the mail, the patient completes the test by his or her own volition. At the 30-60-day follow up reminder call, the implementer will discuss the FOBT kit with the patient and if they do not consent to the screening, it will be noted to their EMR for future reference.

Guidelines for Implementing the	Appendix Attached:	🗆 Yes	🗹 No
Order/Procedure:			

The purpose of this medical directive is to enhance TCFHT patients' access to CRC screening, which is in accordance with provincial cancer screening guidelines "Cancer Care Ontario Guidelines for Breast, Cervical, & Colorectal Cancer Screening" (Cancer Care Ontario, 2016).

Documentation and Communication:	Appendix Attached:	🗆 Yes	☑ No	
----------------------------------	--------------------	-------	------	--

Implementers will document that they have reviewed an eligible patient's EMR and ordered an FOBT using the "Turning 50 CRC (FOBT) Screening Program" Encounter Assistant custom form.

The implementer will send a message in Practice Solutions to the patient's primary care provider, indicating that they have ordered an FOBT for the patient.

The implementer will send a delayed message to themselves in 60 days to follow up with the patient via phone if the FOBT test is not completed within this timeframe. After this 60 day follow up phone call, no further follow up is required.

Review and Quality Monitoring Guidelines:	Appendix Attached:	🗆 Yes	⊠ No	
• Routine review will occur annually on the anniv	ersary of the activation	on date.	Review will involve a	

- collaboration between the authorizing primary care providers and the approved implementers.If new information becomes available between routine reviews, such as the publishing of new
- clinical practice guidelines, and particularily if this new information has implications for unexpected outcomes, the directive will be reviewed by an authorizing primary care provider and a mimimum of one implementer

TCFHT-MD01_Fecal Occult Blood Test

- At any such time that issues related to the use of this directive are identified, TCFHT must act upon the concerns and immediately undertake a review of the directive by the authorizing primary care providers and the authorized implementers.
- This medical directive can be placed on hold if routine review processes are not completed, or if indicated for an ad hoc review. During the hold, implementers cannot perform the procedures under authority of the directive and must obtain direct, patient-specific orders for the procedure until it is renewed.

References:

Cancer Care Ontario. (2016). *Cancer screening guidelines for breast, cervical, & colorectal cancer screening*. Retrieved from

https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=273767

- Cancer Care Ontario. (2016). About ColonCancerCheck. Retrieved from: <u>https://www.cancercareontario.ca/en/cancer-care-ontario/programs/screening-programs/colon-cancer-check-colorectal-screening</u>
- Cancer Care Ontario. (2016). *Screening Guidelines Colon Cancer Check*. Retrieved from https://www.cancercare.on.ca/pcs/screening/coloscreening/cccstandardsguidelines/

Cancer Care Ontario (2018). *Colorectal Cancer Screening Pathway Map*. Accessible from: <u>https://www.cancercareontario.ca/en/pathway-maps/colorectal-cancer</u>

NOTE:

This medical directive is based on TCFHT's previous medical directive PH-1 entitled, "Preventive Health," which required revision in formatting to reflect the growth of the TCFHT organization. The majority of the content of PH-1 has remained the same for the revised TCFHT-MD01 version. Therefore, all approved Implementers and Authorizers for medical directive PH-1 "Preventive Health" have grandfathered approval for TCFHT-MD01 "Fecal Occult Blood Test."

TCFHT-MD01_Fecal Occult I	Appendix A:	
	Authorizer Approval Form	ſ
Name	Signature	Date

Last Updated 21-03-2019 by Vicki McGregor RN

Appendix B:

Implementer Approval Form

To be signed when the implementer has completed the required preparation, and feel they have the

knowledge, skill, and judgement to competently carry out the actions outlined in this directive.

Name	Signature	Date
	Last Updated 21-03-2	019 by Vicki McGregor RN

6

Appendix C:

Preventive Health – CRC Screening Requisition

Ontario Ministry of Health and Long-Term Car Laboratory Requisi Requisitioning Clinic	tion	Lat	oratory Üse Only				
Name							
Trudy Chernin							
Address							
790 Bay Street							
Toronto, ON							
M5G 1N8		Clin	ician/Practitioner's Contact Number for Urg	ent Results	6		Service Date yyyy mm dd
		(416 ⁾ 960-1366				
Clinician/Practitioner Number	CPSO / Registration No.	Hea	Ith Number	Version	Sex		Date of Birth yyyy mm dd
271858		ON	1112 223 456		X M	□F	1930 10 11
Check (1/2) one:		Pro	vince Other Provincial Registration Number	r		Patient	s Telephone Contact Number
X OHIP/Insured Dirich Party / U	ninsured 🗌 WSIB		(416) 555-5555				
Additional Clinical Information (e.g. diagno	osis)	Pat	ent's Last Name (as per OHIP Card)			\ 4	10 / 333-3333
radiational chillion internation (e.g. diagne		1_					
		Du					<u> </u>
		Pat	ent's First & Middle Names (as per OHIP C	ard)			
		Do	nald				
Copy to: Clinician/Practitioner		Pat	ent's Address (including Postal Code)				
Last Name: First	Name	18	7 Bay Street				
Address			ronto. ON				
Address			N 5J5				
		114	11 355				
Noto, Concrete requisitions are r	autod for outology b	intal	ogy / pathology and tests performe	d by Dub		alth I ah	oratory
	equired for cytology, in						
X Biochemistry		X	Hematology				atitis (check one only)
Glucose	n 🗌 Fasting		CBC			Acute Hep	atitis
HbA1C			Prothrombin Time (INR)		(Chronic He	patitis
TSH			Immunology				atus / Previous Exposure
Creatinine (eGFR)			Pregnancy test (Urine)				Hepatitis A
Uric Acid			Mononucleosis Screen		Hepatitis B		
Sodium			Rubella		 Hepatitis C or order individual hepatitis tests in the 		
Potassium			Prenatal: ABO, RhD, Antibody Screen			Other Tes	ts" section below
Chloride		-	(titre and ident. if positive)	- E	Prost	ate Spec	cific Antigen (PSA)
СК		+	Repeat Prenatal Antibodies	_		tal PSA	Free PSA
ALT					_		
Alk. Phosphatase		-	Microbiology ID & Sensitivities (if warranted)		Specify one below: Insured – Meets OHIP eligibility criteria Uninsured – Screening: Patient responsible for payment		
Bilirubin			· · ·				
		-					
Albumin			Vaginal				• •
Lipid Assessment (includes Cholest calculated LDL-C & Chol/HDL-C rati	io; individual lipid tests may		Vaginal / Rectal – Group B Strep		🗌 Ins	sured – Me	ets OHIP eligibility criteria: teopenia; osteoporosis; rickets;
be ordered in the "Other Tests" section	on of this form)	_	Chlamydia (specify source):		renal disease; malabsorption syndromes; medications affecting vitamin D metabolism		
Vitamin B12		_	GC (specify source):				edications affecting vitamin D metabolism Patient responsible for payment
Ferritin			Sputum			- 00 - 1501	
Albumin / Creatinine Ratio, Urine			Throat		Other	r Tests –	one test per line
Urinalysis (Chemical)			Wound (specify source):				
Neonatal Bilirubin:			Urine				
Child's Age: day:	s hours		Stool Culture				
Clinician/Practitioner's tel. no. ()		Stool Ova & Parasites				
Patient's 24 hr telephone no. ()		Other Swabs / Pus (specify source):				
Therapeutic Drug Monitoring:	,						
Name of Drug #1		Sp	ecimen Collection				
Name of Drug #2		Tin		/dd			
Time Collected #1	hr. #2 hr.	Fe	cal Occult Blood Test (FOBT) (chec				
Time of Last Dose #1				,	EODT		that toot oon he ordered on this form
Time of Next Dose #1			/ \	icercheck	LORI		other test can be ordered on this form
	hr. #2 hr.		oratory Use Only				
I hereby certify the tests ordered are r out patients of a hospital.	ioi ior regisierea in or						
Medical Directive #TCFHT-MD01							
X Clinician/Practitioner Signature							

4422-84 (2010/09) ©Queen's Printer for Ontario, 2010

7530-4581

Last Updated 21-03-2019 by Vicki McGregor RN

Appendix D:

Turning 50 CRC Screening (FOBT) Letter

Implementer Name Implementer Taddle Creek FHT Contact Information

Date

Dear Patient's First Name,

I am the Registered Nurse that works with your primary care provider. Our records show that you will soon be turning 50 years old. Happy Birthday! This is an important milestone in your life and an opportunity to focus on your health. As part of your primary care team, I'm committed to helping you be as healthy as possible. A key part of maintaining your health is the prevention and screening of chronic diseases. Our records show that you are due for colorectal cancer screening:

<u>Colorectal Cancer Screening</u> – Adults aged 50 to 74 are encouraged to do the Fecal Occult Blood Test (FOBT) every 2 years. I have included an FOBT kit in this package. Please review the instructions, do the FOBT test as soon as you can, and pop the kit in the mail when you're done.</u> FOBT has been found to decrease the risk of dying from colorectal cancer. A person with colorectal cancer has a 90% chance of being cured if the cancer is caught early with screening.

Go to <u>www.youtube.com</u> and search "Home Screening for Colon Cancer (FOBT)" for more details.

Note: If you have a personal or family history of colorectal cancer, FOBT screening may not be appropriate. In this case, please contact us to discuss what screening is recommended for you.

If in 2 months we have not received your FOBT results, I will call you to follow up. As part of your primary care team, I appreciate the opportunity to work with you to enhance your health and prevent illness. Should you have any questions or concerns, feel free to contact me.

Yours truly,

Implementer Name and Signature